Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?

Updated estimates of pharmaceutical company payments to physicians in Vermont.

1. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-offunction mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524-2532. 2. Singaraja RR, Visscher H, James ER, et al. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ R...

Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota.

CONTEXT Recent legislation in 5 states and the District of Columbia mandated state disclosure of payments made to physicians by pharmaceutical companies. In 2 of these states, Vermont and Minnesota, payment disclosures are publicly available. OBJECTIVES To determine the accessibility and quality of the data available in Vermont and Minnesota and to describe the prevalence and magnitude of dis...

Japanese Practicing Physicians' Relationships with Pharmaceutical Representatives: A National Survey

BACKGROUND Previous surveys on the relationship between physicians and pharmaceutical representatives (PRs) have been of limited quality. The purpose of our survey of practicing physicians in Japan was to assess the extent of their involvement in pharmaceutical promotional activities, physician characteristics that predict such involvement, attitudes toward relationships with PRs, correlations ...

The captive medical malpractice insurance company alternative.